Full View

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

L Pagano, J Salmanton-García… - Blood, The Journal …, 2022 - ashpublications.org
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
被引用次数：65 相关文章

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.

L Pagano, J Salmanton-García, F Marchesi, O Blennow… - Blood, 2022 - europepmc.org
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.

L Pagano, J Salmanton-García, F Marchesi, O Blennow… - 2022 - mediatum.ub.tum.de
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

L Pagano, J Salmanton-García, F Marchesi… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

L Pagano, J Salmanton-García, F Marchesi, O Blennow… - Blood, 2022 - hal.umontpellier.fr
Limited data have been published on the epidemiology and outcomes of breakthrough
COVID-19 in patients with hematological malignancy (HM) after anti-SARS-CoV-2 …
[HTML] nih.gov

[HTML][HTML] Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

L Pagano, J Salmanton-García, F Marchesi, O Blennow… - Blood, 2022 - ncbi.nlm.nih.gov
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

L Pagano, J Salmanton-García, F Marchesi, O Blennow… - BLOOD, 2022 - air.unimi.it
Limited data have been published on the epidemiology and outcomes of breakthrough
COVID-19 in patients with hematological malignancy (HM) after anti-SARS-CoV-2 …

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

L Pagano, J Salmanton-García, F Marchesi, O Blennow… - 2022 - digital.csic.es
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML] ugent.be

[HTML][HTML] Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

L Pagano, J Salmanton-García, F Marchesi, O Blennow… - BLOOD, 2022 - biblio.ugent.be
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) …
[HTML] cabidigitallibrary.org

[HTML][HTML] Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.

L Pagano, J Salmanton-García, F Marchesi, O Blennow… - 2022 - cabidigitallibrary.org
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …